Related Experiment Video
Updated: Jan 4, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Darolutamide For Castration-Resistant Prostate Cancer
Diogo A Bastos1, Emmanuel S Antonarakis2
1Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil.
Abstract:
The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone, enzalutamide and apalutamide) have demonstrate significant improvements in survival and important secondary endpoints. For non-metastatic castration-resistant prostate cancer, recent phase III placebo-controlled trials with enzalutamide, apalutamide and darolutamide all demonstrated benefits in improving metastasis-free survival. This review aims to summarize the clinical development of darolutamide, a novel next-generation androgen receptor antagonist, including preclinical data, clinical studies and the potential of darolutamide for the treatment of advanced prostate cancer. To date, darolutamide efficacy and tolerability has been demonstrated in the ARAMIS trial, which demonstrated an improvement in metastasis-free survival compared to placebo for non-metastatic castration-resistant prostate cancer patients with a rapid PSA doubling time. Ongoing studies will further evaluate the role of darolutamide in metastatic castration-sensitive prostate cancer in combination with docetaxel (ARASENS trial) and also in other stages of the disease.
Insights
Darolutamide, a novel androgen receptor antagonist, shows improved metastasis-free survival in advanced prostate cancer. Ongoing trials are evaluating its role in earlier disease stages and combinations.
Area of Science:
- Oncology
- Pharmacology
- Urology
Background:
- The advanced prostate cancer treatment landscape is rapidly evolving with improved survival outcomes.
- Next-generation androgen receptor-signaling inhibitors demonstrate significant benefits in metastatic and non-metastatic castration-resistant prostate cancer.
- Darolutamide is a novel androgen receptor antagonist with potential in advanced prostate cancer treatment.
Purpose of the Study:
- To review the clinical development of darolutamide, including preclinical data and clinical studies.
- To summarize the efficacy and tolerability of darolutamide in advanced prostate cancer.
- To discuss the potential role of darolutamide in various stages of prostate cancer.
Main Methods:
- Review of preclinical data and clinical studies on darolutamide.
- Analysis of data from the ARAMIS trial for non-metastatic castration-resistant prostate cancer.
- Inclusion of ongoing studies like ARASENS for metastatic castration-sensitive prostate cancer.
Main Results:
- The ARAMIS trial demonstrated improved metastasis-free survival for darolutamide versus placebo in non-metastatic castration-resistant prostate cancer.
- Darolutamide showed favorable efficacy and tolerability in patients with rapid PSA doubling time.
- Ongoing studies are investigating darolutamide in combination therapies and earlier disease stages.
Conclusions:
- Darolutamide is a promising next-generation androgen receptor antagonist for advanced prostate cancer.
- The drug has shown significant benefits in metastasis-free survival for specific patient populations.
- Further research will define darolutamide's broader role in prostate cancer treatment.
